Ex Vivo News and Research

RSS

Study shows how genetic variants control immune cell response to pathogens

A study that is first in its kind and published in Nature Medicine today has looked at how far genetic factors control the immune cell response to pathogens in healthy individuals.

4 Jul 2016

Gene editing technology helps excise segment of HIV-1 DNA from genomes of living animals

Using gene editing technology, researchers at the Lewis Katz School of Medicine at Temple University have, for the first time, successfully excised a segment of HIV-1 DNA - the virus responsible for AIDS - from the genomes of living animals.

20 May 2016

New bio-mimicry method allows scientists to track cells in vivo using MRI during preclinical, clinical trials

Researchers led by Carnegie Mellon University Professor of Biological Sciences Chien Ho have developed a new method for preparing mesenchymal stem cells (MSCs) that not only leads to the production of more native stem cells, but also labels them with a FDA approved iron-oxide nanoparticle (Ferumoxytol).

18 May 2016

Scientists prove effectiveness of gene editing system in eliminating HIV from DNA of CD4+ T-cells

In 2014, a team of researchers in the Lewis Katz School of Medicine at Temple University became the first to successfully eliminate the HIV-1 virus from cultured human cells.

12 May 2016

Exercise may promote cardiovascular health in chronically stressed individuals

Constant stress is associated with signs of poor blood vessel health and increased risk of cardiovascular disease. New research presented today at the Experimental Biology 2016 meeting in San Diego finds that aerobic exercise kept the blood vessels of stressed rats working normally.

6 Apr 2016

Researchers explore rapid changes in oxygen levels as aggravating factors in lung failure

Mechanical ventilation can contribute to lung damage by inducing rapid changes in oxygen levels. Researchers at the Medical University of Vienna are now conducting studies for the first time into the significance of these changes as aggravating factors in lung failure.

5 Apr 2016

Researchers demonstrate novel method for imaging engineered nanoparticles in tissues

As a testament to Governor Andrew Cuomo’s leadership in developing an unparalleled research and development ecosystem in New York State, Sara Brenner, MD, MPH and her colleagues at SUNY Polytechnic Institute (SUNY Poly), the George Washington School of Medicine and Health Sciences, and Stony Brook University have demonstrated a novel method for the rapid visualization and identification of engineered nanoparticles in tissues.

28 Mar 2016

Transient contractions could be new target for therapeutic intervention in urinary bladder dysfunction

Researchers at the University of Vermont College of Medicine have made a discovery that helps explain how we know when to empty our bladders and may lead to new therapeutic interventions for bladder dysfunction.

28 Mar 2016

Specialized gene editing system paves way to eventual cure for HIV patients

A specialized gene editing system designed by scientists at the Lewis Katz School of Medicine at Temple University is paving the way to an eventual cure for patients infected with HIV, the virus that causes AIDS.

22 Mar 2016

Combining photoimmunotherapy and gene transduction effective against elusive gastric cancer cells

Researchers report photoimmunotherapy to be effective against elusive gastric cancer cells following transduction with the gene that expresses the extracellular domain protein of HER2. The results are published in the journal Small Molecule Therapeutics in February 2016.

15 Mar 2016

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD).

8 Mar 2016

SOM0226 (tolcapone) drug could significantly improve pharmacological treatment of ATTR

Researchers at the Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona (IBB-UAB), in collaboration with the biopharmaceutical company SOM Biotech, located in the Barcelona Science Park (PCB), have published, in Nature Communications, the results of a drug repositioning study in which they describe a powerful drug, SOM0226 (tolcapone) that could significantly improve the pharmacological treatment of familial transthyretin amyloidosis (ATTR).

24 Feb 2016

FDA clears Sangamo BioSciences' SB-318 IND application for treatment of MPS I

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application for SB-318, a single treatment strategy intended to provide a life-long therapy for Mucopolysaccharidosis Type I (MPS I).

8 Feb 2016

Novel quantitative method may reduce or eliminate need for invasive biopsies

Scientists have identified a quantitative method to measure changes in biomarkers, which may reduce or eliminate the need for invasive biopsies. The method, described in the February 2016 issue of The FASEB Journal uses a novel chimera design of DNA and small DNA with a companion contrast agent to allow antibodies to cross cellular membranes.

8 Feb 2016

Molecular imaging and radiochemistry: the importance of instrumentation. An interview with Professor Björn Wängler

Interview conducted with Professor Björn Wängler, Professor for Molecular Imaging and Radiochemistry from Heidelberg University.

From Bruker BioSpin Group 4 Feb 2016

Combined MRI and ultramicroscopy toolkit could help study vessel growth in glioma models in more detail

Stopping the growth of blood vessels in tumours is a key target for glioblastoma therapies, and imaging methods are essential for initial diagnosis and monitoring the effects of treatments. While mapping vessels in tumours has proven a challenge, researchers have now developed a combined magnetic resonance imaging (MRI) and ultramicroscopy 'toolkit' to study vessel growth in glioma models in more detail than previously possible.

3 Feb 2016

New $8.5M research grant aims to address patients affected by severe hemophilia A

People with hemophilia have prolonged abnormal bleeding as a result of trauma. Hemophilia A, also called factor VIII (FVIII) deficiency, is the most common form of the genetic disorder caused by missing or defective blood clotting protein called factor VIII.

23 Dec 2015

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced the presentation of Phase 2 data from two of the Company's ongoing clinical trials (SB-728-1101 Cohort 3* and SB-728-mR-1401) of SB-728-T, which is being developed for the functional control of HIV/AIDS.

11 Dec 2015

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer.

7 Dec 2015

New technique improves accuracy of CRISPR/Cas9 gene editing system

A new CRISPR/Cas9 technology developed by scientists at the University of Massachusetts Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.

19 Nov 2015